Get Updates

No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Cancer Treatment > PARP Inhibitor Therapy

| More

BRCA & HBOC
Toggle Menu

PARP Inhibitor Therapy

Learn how genetic test results may affect medical decisions about cancer treatment.”

Lynparza for Pancreatic Cancer

While FDA has approved Lynparza (also known as olaparib) to treat ovarian and related cancers in women who carry mutations in BRCA1 or BRCA2, and who have received three or more chemotherapy treatments, PARP inhibitors are not currently FDA-approved for treating pancreatic. However, preliminary research looking at lynparza in pancreatic cancer has been promising and trials are ongoing.

The POLO Study is a research study asking the question does maintenance therapy (continuation of treatment after initial chemotherapy is completed) with olaparib (a PARP inhibitor) benefit patients with pancreatic cancer and a BRCA mutation whose tumor has not grown on an initial platinum containing drug regimen but who would otherwise now be getting  a break or pause in their chemotherapy.

Updated 12/27/16

FORCE:Facing Our Risk of Cancer Empowered